Recent advances highlight the complex interplay between tumor-promoting and tumor-suppressing immune signals—such as IL-4Rα-driven progression and IL-24-mediated inhibition—as well as novel targets like ERBB2 and tumor-associated autoantigens. The gene discussed is ERBB2; the disease is neoplasm.